Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus

• Royal Perth Hospital, GPO Box X2213, Perth, WA 6847  daniel.fatovichAThealth.wa.gov.au

---

• 1. Levi CR, on behalf of the Australasian Stroke Unit Network, the New South Wales Greater Metropolitan Transition Taskforce Stroke Initiative, and the Towards A Safer Culture Stroke Expert Working Group. Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus. Med J Aust 2004; 180: 634-636. <MJA full text>
• 2. Hoffman JR. Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little [editorial]. Med J Aust 2003; 179: 333-334. <MJA full text>
• 3. Henry G. Acute stroke management: is there a new standard of care? Emerg Med 2004; 16 (Suppl): A36-A37.
• 4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 1995; 333: 1581-1587.
• 5. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for acute ischaemic stroke. The Cleveland area experience. JAMA 2000; 283: 1151-1158.
• 6. Miller MH. Doubt and ethics. BMJ rapid response, 20 November 2002. Available at: bmj.bmjjournals.com/cgi/eletters/324/7339/723#27166 (accessed Nov 2004).
• 7. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome. The NINDS rt-PA stroke study. Neurology 2000; 55: 1649-1655.